The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice - Archive ouverte HAL Access content directly
Journal Articles Genes and Development Year : 2020

The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice

Abstract

Young mammals possess a limited regenerative capacity in some tissues, which is lost upon maturation. We investigated whether cellular senescence might play a role in such loss during liver regeneration. We found that following partial hepatectomy, the senescence-associated genes p21, p16 Ink4a , and p19 Arf become dynamically expressed in different cell types when regenerative capacity decreases, but without a full senescent response. However, we show that treatment with a senescence-inhibiting drug improves regeneration, by disrupting aberrantly prolonged p21 expression. This work suggests that senescence may initially develop from heterogeneous cellular responses, and that senotherapeutic drugs might be useful in promoting organ regeneration.
Fichier principal
Vignette du fichier
PDF Datastream.pdf (22.28 Mo) Télécharger le fichier
Origin : Explicit agreement for this submission
Licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-03715508 , version 1 (12-01-2023)

Licence

Attribution

Identifiers

Cite

Birgit Ritschka, Tania Knauer-Meyer, Daniel Sampaio Gonçalves, Alba Mas Malavila, Jean-Luc Plassat, et al.. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes and Development, 2020, 34 (7-8), pp.489-494. ⟨10.1101/gad.332643.119⟩. ⟨hal-03715508⟩
60 View
7 Download

Altmetric

Share

Gmail Facebook X LinkedIn More